Hormonal Manipulation of Prostate Cancer

2000 ◽  
pp. 293-311
Author(s):  
Jeffrey M. Kamradt ◽  
Kenneth J. Pienta
Keyword(s):  
Prostate Cancer ◽  
Hormonal Manipulation

Secondary hormonal manipulation of prostate cancer

2001 ◽  
Vol 2 (3) ◽  
pp. 224-230
Author(s):  
Katherine A. Harris ◽  
Eric J. Small
Keyword(s):  
Prostate Cancer ◽  
Hormonal Manipulation

Prognostic Significance of Prostate-Specific Antigen Levels Two Months after Hormonal Manipulation of Metastatic Prostate Cancer

1997 ◽  
Vol 32 (1) ◽  
pp. 58-63 ◽  
Author(s):  
S. (a) Kawakami ◽  
K. (a) Takagi ◽  
T. (b) Ueda ◽  
I. (b) Fukui ◽  
T. (b) Kawai
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Metastatic Prostate Cancer ◽  
Prognostic Significance ◽  
Specific Antigen ◽  
Hormonal Manipulation

ErbB1–4 expression in prostate cancer patients and its correlation to patients’ ethnicity and outcome

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14615-14615
Author(s):  
R. Ben-Yosef ◽  
I. Barnea ◽  
D. Sarid ◽  
A. Vexler ◽  
S. Marmor ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Cancer Progression ◽  
Free Probability ◽  
External Beam Radiation ◽  
Beam Radiation ◽  
Over Expression ◽  
Hormonal Manipulation ◽  
Cancer Specimen ◽  
Worse Prognosis

14615 Background: ErbB family is involved in both cancer progression and treatment response in solid tumors. Few inconclusive studies reported on ErbB over-expression in prostate cancer. We investigated ErbB1–4 expression in prostate cancer patients and its correlation to patients ethnicity and outcome. Methods: ErbB expression was evaluated by immunohistochemistry of prostate cancer specimen using polyclonal antibody (Santa Cruz, CA). The staining was recorded as negative (0/+1), moderately positive (+2) and highly positive (+3). Kattan nomogram was used to predict 5-yr progression-free probability, assuming that all patients received external beam radiation therapy (a total dose of 78 Gy) and hormonal manipulation. Origin was counted in all 43 patients: Ashkenazic patients were defined as those who immigrated from East/West Europe or North America and Sephardic patients - from Middle East and North Africa. Results: ErbB1 (+2/+3) was over-expressed in 12 and 7 patients for a total of 19/43 (44%). ErbB2 over-expression (+2/+3) was not found in all patients. ErbB3 over-expression of +2 was seen in 2 patients and none had +3 (2/43, 5%). ErbB4 over-expression (+2/+3) was seen in 5 and 11 patients for a total of 16/43 (37%). 22 patients were Ashkenazic and 21 - Sephardic. ErbB1 over-expression in Ashkenazic and Sephardic groups was 9/22 (41%) and 10/21 (48%). ErbB4 over-expression in the two groups was 7/22 (32%) and 9/21 (43%). Kattan score of <80 was seen in 20/43 and <60 in 7/43 patients. ErbB1 over-expression was noted in 11/20 and in 4/7 patients. ErbB4 over-expression was seen in 7/20 and in 4/7 patients. In both ErbB1 and ErbB4 over-expression and Kattan nomogram of <80 and <60 the Sephardic ethnicity dominated-7/11 (64%), 3/4 (75%), 5/7 (71%) and 3/4 (75%). Conclusions: ErbB1 and ErbB4 over-expression is presented in 43% and 37% patients while ErbB3 was over-expressed in 5%; no over-expression of ErbB2 was observed. Ashkenazic and Sephardic ethnicity were evenly distributed in the over-expressed ErbB1 and ErbB4 patients. However, a tendency to a worse prognosis, based on Kattan nomogram, was seen in over-expressed ErbB1 and ErbB4 patients from Sephardic ethnicity. Further studies on ethnicity and ErbB prevalence and prognosis are warranted. No significant financial relationships to disclose.

scholarly journals Strategies for Imaging Androgen Receptor Signaling Pathway in Prostate Cancer: Implications for Hormonal Manipulation and Radiation Treatment

2013 ◽  
Vol 2013 ◽  
pp. 1-6
Author(s):  
Gravina Giovanni Luca ◽  
Claudio Festuccia ◽  
Pierluigi Bonfili ◽  
Mario Di Staso ◽  
Pietro Franzese ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Molecular Imaging ◽  
Radiation Treatment ◽  
Oncological Outcome ◽  
Biological Information ◽  
Treatment Modalities ◽  
Receptor Signaling ◽  
Androgen Receptor Signaling ◽  
Hormonal Manipulation

Prostate cancer (Pca) is a heterogeneous disease; its etiology appears to be related to genetic and epigenetic factors. Radiotherapy and hormone manipulation are effective treatments, but many tumors will progress despite these treatments. Molecular imaging provides novel opportunities for image-guided optimization and management of these treatment modalities. Here we reviewed the advances in targeted imaging of key biomarkers of androgen receptor signaling pathways. A computerized search was performed to identify all relevant studies in Medline up to 2013. There are well-known limitations and inaccuracies of current imaging approaches for monitoring biological changes governing tumor progression. The close integration of molecular biology and clinical imaging could ease the development of new molecular imaging agents providing novel tools to monitor a number of biological events that, until a few years ago, were studied by conventional molecular assays. Advances in translational research may represent the next step in improving the oncological outcome of men with Pca who remain at high risk for systemic failure. This aim may be obtained by combining the anatomical properties of conventional imaging modalities with biological information to better predict tumor response to conventional treatments.

Hormonal manipulation of prostate cancer with sequential androgen blockade.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e15033-e15033
Author(s):  
K. B. Olson ◽  
S. Daignault ◽  
D. A. Hamstra ◽  
K. J. Pienta
Keyword(s):  
Prostate Cancer ◽  
Hormonal Manipulation ◽  
Androgen Blockade

scholarly journals Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance?

2021 ◽  
Author(s):  
Christina Niklas ◽  
Matthias Saar ◽  
Alessandro Nini ◽  
Johannes Linxweiler ◽  
Stefan Siemer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Biochemical Recurrence ◽  
Metastatic Prostate Cancer ◽  
Locally Advanced ◽  
Survival Rates ◽  
Term Survival ◽  
Long Term Survival ◽  
Hormonal Manipulation

Abstract Purpose A number of observational clinical studies suggest that prior primary tumor treatment favorably influences the course of metastatic prostate cancer (PCa), but its mechanisms of action are still speculative. Here, we describe the long-lasting sensitivity to various forms of androgen deprivation in patients after radical prostatectomy (RP) for locally advanced PCa as one potential mechanism. Methods A consecutive series of 115 radical prostatectomies after inductive therapy for T4 prostate cancer was re-analyzed, and long-term survival, as well as recurrence patterns and responses to different forms of hormonal manipulation, were assessed. Results The estimated biochemical response-free, PCa-specific, and overall survival rates after 200 months were 20%, 65%, and 47% with a median overall survival of 156 months. The majority of patients, although not cured of locally advanced PCa (84/115), showed long-term survival after RP. PCa-specific and overall survival rates of these 84 patients with biochemical recurrence were 61% and 44% at 150 months. Long-term sensitivity to ADT was found to be the main reason for the favorable tumor-specific survival in spite of biochemical recurrence. Conclusions Sensitivity to primary or secondary hormonal manipulation was the main reason for the long-term survival of patients who had not been cured by surgery only. The results suggest that treatment of the primary tumor-bearing prostate delays castration-resistant PCa and enhances the effect of hormonal therapies in a previously unknown manner. The underlying cellular and molecular mechanisms need to be explored in more detailed analyses, which could profoundly impact treatment concepts of locally advanced and metastatic PCa.

Sign in / Sign up

Export Citation Format

Share Document